AIMS: Attention-Deficit/Hyperactivity Disorder (ADHD) is widely regarded as a common comorbidity of methamphetamine (MA) dependence, but the frequency, persistence, and real-world impact of ADHD among MA users are not known. METHODS: Four hundred individuals with MA use disorders within 18months of evaluation and 355 non-MA using comparison subjects completed a comprehensive neuropsychiatric research battery, including self-report measures of everyday functioning. RESULTS: In logistic regression models adjusting for potential confounds, lifetime diagnoses of ADHD as determined by a structured clinical interview were significantly more prevalent among the MA participants (21%) versus comparison subjects (6%), particularly the hyperactive and combined subtypes. MA use was also associated with an increased persistence of combined subtype of ADHD into adulthood. Among the MA users, lifetime ADHD diagnoses were uniquely associated with greater concurrent risk of declines in instrumental activities of daily living, elevated cognitive symptoms in day-to-day life, and unemployment. CONCLUSIONS: Findings indicate that ADHD is prevalent among chronic MA users, who are at increased risk for persistence of childhood diagnoses of ADHD into their adult years. ADHD also appears to play an important role in MA-associated disability, indicating that targeted ADHD screening and treatment may help to improve real-world outcomes for individuals with MA use disorders.
AIMS: Attention-Deficit/Hyperactivity Disorder (ADHD) is widely regarded as a common comorbidity of methamphetamine (MA) dependence, but the frequency, persistence, and real-world impact of ADHD among MA users are not known. METHODS: Four hundred individuals with MA use disorders within 18months of evaluation and 355 non-MA using comparison subjects completed a comprehensive neuropsychiatric research battery, including self-report measures of everyday functioning. RESULTS: In logistic regression models adjusting for potential confounds, lifetime diagnoses of ADHD as determined by a structured clinical interview were significantly more prevalent among the MA participants (21%) versus comparison subjects (6%), particularly the hyperactive and combined subtypes. MA use was also associated with an increased persistence of combined subtype of ADHD into adulthood. Among the MA users, lifetime ADHD diagnoses were uniquely associated with greater concurrent risk of declines in instrumental activities of daily living, elevated cognitive symptoms in day-to-day life, and unemployment. CONCLUSIONS: Findings indicate that ADHD is prevalent among chronic MA users, who are at increased risk for persistence of childhood diagnoses of ADHD into their adult years. ADHD also appears to play an important role in MA-associated disability, indicating that targeted ADHD screening and treatment may help to improve real-world outcomes for individuals with MA use disorders.
Authors: David J Moore; Kaitlin Blackstone; Steven Paul Woods; Ronald J Ellis; J Hampton Atkinson; Robert K Heaton; Igor Grant Journal: AIDS Care Date: 2012-04-24
Authors: Joseph Biederman; Eric Mick; Stephen V Faraone; Ellen Braaten; Alysa Doyle; Thomas Spencer; Timothy E Wilens; Elizabeth Frazier; Mary Ann Johnson Journal: Am J Psychiatry Date: 2002-01 Impact factor: 18.112
Authors: Julie D Rippeth; Robert K Heaton; Catherine L Carey; Thomas D Marcotte; David J Moore; Raul Gonzalez; Tanya Wolfson; Igor Grant Journal: J Int Neuropsychol Soc Date: 2004-01 Impact factor: 2.892
Authors: R de Graaf; R C Kessler; J Fayyad; M ten Have; J Alonso; M Angermeyer; G Borges; K Demyttenaere; I Gasquet; G de Girolamo; J M Haro; R Jin; E G Karam; J Ormel; J Posada-Villa Journal: Occup Environ Med Date: 2008-05-27 Impact factor: 4.402
Authors: Erica Weber; Kaitlin Blackstone; Jennfer E Iudicello; Erin E Morgan; Igor Grant; David J Moore; Steven Paul Woods Journal: Drug Alcohol Depend Date: 2012-05-03 Impact factor: 4.492
Authors: Kaitlin Blackstone; Jennifer E Iudicello; Erin E Morgan; Erica Weber; David J Moore; Donald R Franklin; Ronald J Ellis; Igor Grant; Steven Paul Woods Journal: J Addict Med Date: 2013 Jul-Aug Impact factor: 3.702
Authors: Sharlene Kaye; Josep Antoni Ramos-Quiroga; Geurt van de Glind; Frances R Levin; Stephen V Faraone; Steve Allsop; Louisa Degenhardt; Franz Moggi; Csaba Barta; Maija Konstenius; Johan Franck; Arvid Skutle; Eli-Torild Bu; Maarten W J Koeter; Zsolt Demetrovics; Máté Kapitány-Fövény; Robert A Schoevers; Katelijne van Emmerik-van Oortmerssen; Pieter-Jan Carpentier; Geert Dom; Sofie Verspreet; Cleo L Crunelle; Jesse T Young; Susan Carruthers; Joanne Cassar; Melina Fatséas; Marc Auriacombe; Brian Johnson; Matthew Dunn; Ortal Slobodin; Wim van den Brink Journal: J Atten Disord Date: 2016-02-27 Impact factor: 3.256
Authors: Annie P Odell; Grace L Reynolds; Dennis G Fisher; Loucine M Huckabay; William C Pedersen; Pamela Xandre; Milica Miočević Journal: J Nerv Ment Dis Date: 2017-05 Impact factor: 2.254
Authors: Jorge A Avila; Roseanna M Zanca; Denis Shor; Nicholas Paleologos; Amber A Alliger; Maria E Figueiredo-Pereira; Peter A Serrano Journal: Heliyon Date: 2018-02-02
Authors: James R Gooden; Vanessa Petersen; Georgia L Bolt; Ashlee Curtis; Victoria Manning; Catherine A Cox; Dan I Lubman; Shalini Arunogiri Journal: Front Psychiatry Date: 2022-02-14 Impact factor: 4.157